

AMENDMENT C
(37 C.F.R. 1.116)

IN THE CLAIMS:

Please amend claims 1, 15, 20, 21 and 22 in accordance with 37 C.F.R. 1.121.

The claims are attached herein on separate sheets.

AMENDMENT TO CLAIMS

[Deleted material is struck-through and added material is underlined]

1. (Currently Amended) A composition for treating symptoms and conditions associated with aging, the composition including an active ingredient consisting essentially of:
one of

an aqueous extract of buckwheat seed extracted at a temperature of between 61 °C and 150 °C,

a fractionation product of an aqueous extract of buckwheat seed, and

a combination of said aqueous extract of buckwheat seed and said fractionation product of said aqueous extract of buckwheat seed,

wherein the active ingredient contains polymers having 4 to 9 monomer units, said polymers having a molecular weight of from about 1,000 to about 10,000,

wherein the composition enhances an activity of protein kinase C (PKC), improves short time memory and alleviates decrease in space cognition caused by aging.

2. (Original) The composition according to Claim 1, wherein the aqueous extract of buckwheat seed has a molecular weight of about 1500 or more.

3. (Previously Presented) The composition according to Claim 1, wherein the composition alleviates and treats symptoms and conditions caused by dementia.

4. (Previously Presented) The composition according to Claim 2, wherein the composition alleviates and treats symptoms and conditions caused by dementia.

5. (Previously Presented) The composition according to Claim 1, wherein the composition alleviates and treats symptoms and conditions caused by Alzheimer's syndrome.

6. (Previously Presented) The composition according to Claim 2, wherein the composition alleviates and treats symptoms and conditions caused by Alzheimer's syndrome.


7. (Previously Presented) The composition according to Claim 1, wherein the composition inhibits lipid peroxide.

8. (Previously Presented) The composition according to Claim 2, wherein the composition inhibits lipid peroxide.

9. (Previously Presented) The composition according to Claim 1, wherein the composition treats hyperlipemia.



- | | | |
|-----|------------------------|---|
| 10. | (Previously Presented) | The composition according to Claim 2, wherein the composition treats hyperlipemia. |
| 11. | (Previously Presented) | The composition according to Claim 1, wherein the composition lowers triacylglycerol levels. |
| 12. | (Previously Presented) | The composition according to Claim 2, wherein the composition lowers triacylglycerol levels. |
| 13. | (Previously Presented) | The composition according to Claim 1, wherein the composition lowers cholesterol levels. |
| 14. | (Previously Presented) | The composition according to Claim 2, wherein the composition lowers cholesterol levels. |
| 15. | (Currently Amended) | The composition according to Claim 1, wherein the polymer having four to nine monomer units <u>consists essentially of</u> comprises a catechin-epicatechin polymer having four to nine monomer units. |

16. (Previously Presented) The composition according to Claim 1, wherein the polymers having four to nine monomer units consist essentially of catechin-epicatechin polymers of the formula:





wherein n has a value of from 2 to 7, and

R is


..... OH and  OH and the ratio of OH to  OH is 2 to 1,

R' is

..... OH and  OH and the ratio of OH to  OH is 1 to 2



giving a ratio of catechin to epicatechin in the upper terminal and middle of 2 to 1 and a 1 to 2 ratio of catechin to epicatechin in the lower terminal.

17. (Original) The composition of claim 16 wherein n has a value of 3.
18. (Original) The composition of claim 16 wherein n has a value of 5.
19. (Original) The composition of claim 16 wherein n has a value of 7.
20. (Currently Amended) The composition of claim 2 wherein the catechin-epicatechin polymer consists essentially of ~~comprises~~ an catechin-epicatechin oligomer.
21. (Currently Amended) A method of improving the memory of humans and animals comprising administering to said humans and animals an effective amount of a composition having an active ingredient consisting essentially of:
- one of
- an aqueous extract of buckwheat seed,
 - a fractionation product of an aqueous extract of buckwheat seed, and
 - a combination of said aqueous extract of buckwheat seed and said fractionation product of said aqueous extract of buckwheat seed,
- wherein the active ingredient contains polymers having 4 to 9 monomer units, said polymers having a molecular weight of from about 1,000 to about 10,000, and
- wherein the polymers having 4 to 9 monomer units consist essentially of catechin-epicatechin polymers of the formula:



wherein n has a value of from 2 to 7, and

R is

..... OH and  OH and the ratio of OH to  OH is 2 to 1,

R' is

..... OH and  OH and the ratio of OH to  OH is 1 to 2

giving a ratio of catechin to epicatechin in the upper terminal and middle of 2 to 1 and a 1 to 2 ratio of catechin to epicatechin in the lower terminal

wherein the composition enhances an activity of protein kinase C (PKC), improves short time memory and alleviates decrease in space cognition caused by aging.

22. (Currently Amended) A pharmaceutical product which includes as an agent, a polyphenol oligomer which is hot-water extracted from buckwheat seeds at a temperature of

between 61 °C and 150 °C, and contains catechin and epicatechins at a ~~specific~~ ratio of catechin to epicatechin in an upper terminal and middle of 2 to 1 and a 1 to 2 ratio of catechin to epicatechin in a lower terminal.

wherein the polyphenol oligomer has 4 to 9 monomer units and said polyphenol oligomer has a molecular weight of about 1000 to about 10,000, and

which enhances an activity of protein kinase C (PKC), improves short time memory and alleviates decrease in space cognition caused by aging.